Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

 

Payments by Drug and Medical Device Manufacturers to US Peer Reviewers of Major Medical Journals

Nguyen et al., JAMA, doi:10.1001/jama.2024.17681
Oct 2024  
  Post
  Facebook
Share
  Source   PDF  
Analysis of payments by drug and medical device manufacturers to US physician peer reviewers of 4 major medical journals from 2020-2022. Authors found that 59% of 1,962 eligible reviewers received industry payments totaling over $US1 billion, with a median payment of $US 31,254 per physician.
Nguyen et al., 10 Oct 2024, Canada, peer-reviewed, 7 authors. Contact: wallis.cjd@gmail.com.
This PaperMiscellaneousAll
Abstract: Letters RESEARCH LETTER Payments by Drug and Medical Device Manufacturers to US Peer Reviewers of Major Medical Journals Table 1. Industry Payments to US Physician Peer Reviewers (N = 1962) From 4 Major Medical Journals, 2020-2022 Characteristics Although conflicts of interest of journal editors and authors have been investigated,1,2 the traditionally opaque nature of peer review has hindered their evaluation among peer reviewers, despite their crucial role in academic publishing. While most journals have established conflict of interest Supplemental content policies for authors, fewer extend these policies to peer reviewers.3 In many cases, journals or editors may inquire about reviewer conflicts of interest and consider these while managing the peer review process, although publicly available reviewer conflict of interest disclosures are rare. Reviewers of leading medical journals may have industry ties due to their academic expertise. We sought to characterize payments by drug and medical device manufacturers to US peer reviewers of major medical journals. Methods | We identified peer reviewers for The BMJ, JAMA, The Lancet, and The New England Journal of Medicine (NEJM) using each journal’s 2022 reviewer list. These journals were selected for their high impact factor and reputation as leading publications of original general medical research. Because reviewer lists did not include affiliations, identification was conducted using Scopus and the National Plan and Provider Enumeration System, which also provided sex and specialty information. We limited our cohort to US-based physicians due to use of the Centers for Medicare & Medicaid Services Open Payments database. Two independent abstractors (A.-L.N., L.M.) performed the search strategy for each reviewer, with discrepancies resolved by a third author (D.-D.N.). We extracted general and research payments to the identified peer reviewers between 2020 and 2022 from the Open Payments database, capturing payments from drug and medical device manufacturers to US-licensed physicians.4 We excluded ownership and investment interests because they are not equivalent to financial transfers and are less reliable than other general payments. Research payments included payments to individual physicians and institutional payments for research where they served as principal investigators. Institutional payments were divided by the number of principal investigators. Inflation-adjusted payment amounts in 2022 US dollars were calculated among those receiving payments. We compared industry payments by sex and specialty using the Mann-Whitney U test and Kruskal-Wallis test with subsequent Dunn pairwise testing accounting for multiple testing, respectively. Analyses were performed using Stata MP version 17.0 (StataCorp). Statistical significance was defined as a 2-sided P < .05. jama.com Value Reviewers accepting payments, No. (%) General payments 1060 (54.0) Research paymentsa 623 (31.8) Any payments 1155 (58.9) Total payments, $ General payments 64 181 780 Research paymentsa 1 004 488 143 Overall 1 068 669 920 Payment received per physician, median (IQR), $b General payments 7614 (495-43 069) Research paymentsa 153 173 (29 307-835 637) Overall 31 254 (2000-276 958) Total payments by category, $ (%) Research payments via institutions (associated research funding)c 999 197 635 (93.5) Consulting fees 34 313 903 (3.2) Speaking compensation not related to CME program 11 801 491..
{ 'indexed': { 'date-parts': [[2024, 10, 11]], 'date-time': '2024-10-11T04:20:15Z', 'timestamp': 1728620415226}, 'reference-count': 5, 'publisher': 'American Medical Association (AMA)', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>This study characterizes payments by drug and medical device manufacturers to US peer ' 'reviewers of major medical journals.</jats:p>', 'DOI': '10.1001/jama.2024.17681', 'type': 'journal-article', 'created': { 'date-parts': [[2024, 10, 10]], 'date-time': '2024-10-10T15:02:21Z', 'timestamp': 1728572541000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Payments by Drug and Medical Device Manufacturers to US Peer Reviewers of Major Medical Journals', 'prefix': '10.1001', 'author': [ { 'given': 'David-Dan', 'family': 'Nguyen', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Urology, University of Toronto, Toronto, Ontario, ' 'Canada'}, { 'name': 'Institute of Health Policy, Management, and Evaluation, ' 'University of Toronto, Toronto, Ontario, Canada'}]}, { 'given': 'Anju', 'family': 'Muramaya', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Medicine, Tohoku University, Sendai City, Miyagi, ' 'Japan'}, { 'name': 'Department of Population Health Science and Policy, Icahn School ' 'of Medicine at Mount Sinai, New York, New York'}]}, { 'given': 'Anna-Lisa', 'family': 'Nguyen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Schulich School of Medicine and Dentistry, Western University, ' 'Windsor, Ontario, Canada'}]}, { 'given': 'Alan', 'family': 'Cheng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Michael G. DeGroote School of Medicine, McMaster University, ' 'Hamilton, Ontario, Canada'}]}, { 'given': 'Liam', 'family': 'Murad', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Medicine and Health Sciences, McGill University, ' 'Montreal, Quebec, Canada'}]}, { 'given': 'Raj', 'family': 'Satkunasivam', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Urology, Houston Methodist Hospital, Houston, ' 'Texas'}]}, { 'given': 'Christopher J. D.', 'family': 'Wallis', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Urology, University of Toronto, Toronto, Ontario, ' 'Canada'}, { 'name': 'Division of Urology, Mount Sinai Hospital, Toronto, Ontario, ' 'Canada'}]}], 'member': '10', 'published-online': {'date-parts': [[2024, 10, 10]]}, 'reference': [ { 'key': 'jld240062r1', 'doi-asserted-by': 'publisher', 'first-page': 'j4619', 'DOI': '10.1136/bmj.j4619', 'article-title': 'Payments by US pharmaceutical and medical device manufacturers to US ' 'medical journal editors: retrospective observational study.', 'volume': '359', 'author': 'Liu', 'year': '2017', 'journal-title': 'BMJ'}, { 'issue': '4', 'key': 'jld240062r2', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmjopen-2021-057598', 'article-title': 'A cross-sectional examination of conflict-of-interest disclosures of ' 'physician-authors publishing in high-impact US medical journals.', 'volume': '12', 'author': 'Baraldi', 'year': '2022', 'journal-title': 'BMJ Open'}, { 'issue': '12', 'key': 'jld240062r3', 'doi-asserted-by': 'publisher', 'first-page': '1248', 'DOI': '10.1111/j.1525-1497.2006.00598.x', 'article-title': 'Conflict of interest disclosure policies and practices in peer-reviewed ' 'biomedical journals.', 'volume': '21', 'author': 'Cooper', 'year': '2006', 'journal-title': 'J Gen Intern Med'}, { 'issue': '17', 'key': 'jld240062r5', 'doi-asserted-by': 'publisher', 'first-page': '1785', 'DOI': '10.1001/jama.2020.11413', 'article-title': 'Trends in industry payments to physicians in the United States from ' '2014 to 2018.', 'volume': '324', 'author': 'Marshall', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': 'jld240062r4', 'unstructured': 'Centers for Medicare & Medicaid Services. Open Payments. Accessed June ' '1, 2024. https://openpaymentsdata.cms.gov/'}], 'container-title': 'JAMA', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://jamanetwork.com/journals/jama/articlepdf/2824834/jama_nguyen_2024_ld_240062_1727972553.95638.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 10, 10]], 'date-time': '2024-10-10T15:02:24Z', 'timestamp': 1728572544000}, 'score': 1, 'resource': {'primary': {'URL': 'https://jamanetwork.com/journals/jama/fullarticle/2824834'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 10, 10]]}, 'references-count': 5, 'URL': 'http://dx.doi.org/10.1001/jama.2024.17681', 'relation': {}, 'ISSN': ['0098-7484'], 'subject': [], 'container-title-short': 'JAMA', 'published': {'date-parts': [[2024, 10, 10]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit